A man using Melanotan II for tanning/sexual enhancement suffered a renal infarction (kidney blood flow blockage), adding to growing evidence that this unregulated peptide can cause serious kidney damage.
Renal infarctionA potentially life-threatening kidney blood flow blockage attributed to Melanotan II use — a previously unreported adverse effect of this unregulated tanning peptide
What the researchers found
A case of renal infarction (blood flow blockage to the kidney) was reported in a patient using Melanotan II, a non-selective melanocortin receptor agonist used illicitly for skin tanning and sexual enhancement. The renal infarction was most likely attributed to the Melanotan II use.
The authors propose two possible mechanisms for the kidney injury: a thrombotic (blood clot) effect from the drug's pharmacological action, and a possible direct toxic effect on kidney tissue. Previous reports had already linked Melanotan II to rhabdomyolysis (muscle breakdown) and kidney failure, and this case adds renal infarction to the list of serious adverse events.
Why it matters
Melanotan II is widely available through unregulated online markets and used by thousands of people for tanning and sexual enhancement, despite never being approved for human use by any regulatory agency. Most users are unaware of serious risks like kidney damage. This case report adds renal infarction — a potentially life-threatening condition — to the growing list of documented harms. It also highlights that renal infarction is frequently misdiagnosed or diagnosed late, meaning the actual incidence in Melanotan II users may be higher than reported.
The numbers in context
1 case of renal infarction · Non-selective melanocortin receptor agonist · Prior reports of rhabdomyolysis and renal failure
How the study worked
Case report of a single patient who developed renal infarction in the setting of Melanotan II use, combined with a literature review of Melanotan II's known effects on the kidneys.
Who was studied
Single male patient using Melanotan II who developed renal infarction
What this study cannot tell us
This is a single case report, which cannot prove causation — only an association between Melanotan II use and renal infarction. The patient may have had other risk factors not fully described. The exact mechanism of injury remains hypothetical. Case reports represent the lowest level of clinical evidence.
How to read the evidence
This is a single case report with a literature review — the lowest level of clinical evidence. It can suggest an association but cannot prove Melanotan II caused the renal infarction. However, combined with previous reports of kidney damage, it contributes to a concerning pattern.
When this study was published
Published in 2020. Melanotan II continues to be widely available online despite accumulating safety concerns. This report remains relevant as a warning for users and clinicians.
The bigger picture
Melanotan II represents a broader problem: unregulated peptides sold directly to consumers who use them without medical supervision. As the peptide market grows, so does the documentation of serious adverse events. This case adds to a pattern of kidney-related harms from Melanotan II and underscores the need for public awareness about the risks of self-administering research peptides.
Questions still open
- How common are kidney injuries among Melanotan II users, and how many go undiagnosed or unreported?
- Does Melanotan II cause blood clots through a specific mechanism, or is renal infarction an idiosyncratic reaction?
- Should emergency physicians routinely ask about peptide use when evaluating unexplained kidney events in younger patients?
Common questions
What is a renal infarction and why is it dangerous?
Is Melanotan II approved for human use?
Read the original research
Melanotan II: a possible cause of renal infarction: review of the literature and case report.
CEN case reports, 9(2), 159-161
Citation
Peters, Björn; Hadimeri, Henrik; Wahlberg, Rebecka; Afghahi, Henri. (2020). Melanotan II: a possible cause of renal infarction: review of the literature and case report.. CEN case reports, 9(2), 159-161. https://doi.org/10.1007/s13730-020-00447-z